Pacific Biosciences Grants Equity Incentive Award to New Employee
Pacific Biosciences (NASDAQ: PACB) announced the granting of non-qualified stock options for 110,000 shares and restricted stock units (RSUs) for 55,000 shares to a newly hired employee under its 2020 Inducement Equity Incentive Plan. The options have an exercise price of $35.95 per share, equal to the stock's closing price on January 25, 2021. The options vest over four years, with one-fourth vesting after one year and the rest monthly thereafter. The RSUs will vest annually over four years. This plan aims to attract talent by offering equity awards.
- Granting of stock options and RSUs can attract and retain talent, enhancing workforce stability.
- Options have an exercise price set at the market closing price, potentially aligning employee interests with shareholders.
- None.
MENLO PARK, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 110,000 shares of Pacific Biosciences common stock and restricted stock units (“RSU”) covering 55,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the “2020 Inducement Plan”).
The 2020 Inducement Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pacific Biosciences as an inducement material to such individual’s entering into employment with Pacific Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).
The options have an exercise price of
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.
Contact
Investors: Trevin Rard
650.521.8450
ir@pacificbiosciences.com
FAQ
What stock options were granted by Pacific Biosciences on January 29, 2021?
What is the exercise price for the stock options granted by PACB?
How do the stock options and RSUs vest for Pacific Biosciences employees?